Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADXS
  • CUSIP: N/A
  • Web:
  • Market Cap: $161.39 million
  • Outstanding Shares: 41,065,000
Average Prices:
  • 50 Day Moving Avg: $4.88
  • 200 Day Moving Avg: $6.67
  • 52 Week Range: $3.76 - $10.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $14.01 million
  • Price / Sales: 11.11
  • Book Value: $1.81 per share
  • Price / Book: 2.09
  • EBITDA: ($93,950,000.00)
  • Net Margins: -655.66%
  • Return on Equity: -93.54%
  • Return on Assets: -64.49%
  • Current Ratio: 4.60%
  • Quick Ratio: 4.60%
  • Average Volume: 766,965 shs.
  • Beta: 2.17
  • Short Ratio: 21.4

Frequently Asked Questions for Advaxis (NASDAQ:ADXS)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Monday, September, 11th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.27. The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. View Advaxis' Earnings History.

When will Advaxis make its next earnings announcement?

Advaxis is scheduled to release their next quarterly earnings announcement on Tuesday, January, 16th 2018. View Earnings Estimates for Advaxis.

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2017?

2 brokerages have issued 1-year target prices for Advaxis' stock. Their predictions range from $19.00 to $23.00. On average, they expect Advaxis' share price to reach $21.00 in the next year. View Analyst Ratings for Advaxis.

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:

  • David Sidransky M.D., Independent chairman of the Board of Director
  • Anthony Lombardo, Interim Chief Executive Officer
  • Sara M. Bonstein, Chief Financial Officer, Executive Vice President
  • Robert G. Petit Ph.D., Executive Vice President, Chief Scientific Officer
  • James P. Patton M.D., Non-Executive Independent Vice Chairman of the Board
  • Gregory T. Mayes III, Director
  • Roni A. Appel, Independent Director
  • Richard J. Berman J.D., Independent Director
  • Samir N. Khleif, Independent Director

Who owns Advaxis stock?

Advaxis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (11.45%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of Advaxis stock can currently be purchased for approximately $3.79.

MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (454.09% upside)
Consensus Price Target History for Advaxis (NASDAQ:ADXS)
Price Target History for Advaxis (NASDAQ:ADXS)
Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00HighView Rating Details
9/15/2017HC WainwrightReiterated RatingBuy$23.00LowView Rating Details
9/9/2016Jefferies Group LLCReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Advaxis (NASDAQ:ADXS)
Earnings by Quarter for Advaxis (NASDAQ:ADXS)
Earnings History by Quarter for Advaxis (NASDAQ ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/16/2018($0.55)N/AView Earnings Details
9/11/2017Q3($0.53)($0.80)$3.43 million$3.05 millionViewN/AView Earnings Details
3/10/2017Q1 2017($0.52)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Advaxis (NASDAQ:ADXS)
2017 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.51)($0.51)($0.51)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.61)($0.61)($0.61)
Q4 20171($0.64)($0.64)($0.64)
(Data provided by Zacks Investment Research)


Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Advaxis (NASDAQ:ADXS)
Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 48.06%
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2017Adage Capital Partners Gp, L.LMajor ShareholderSell600,000$4.30$2,580,000.00View SEC Filing  
9/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,239,323$4.42$5,477,807.66View SEC Filing  
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.28View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Advaxis (NASDAQ:ADXS)
Latest Headlines for Advaxis (NASDAQ:ADXS)
DateHeadline logoAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 600,000 Shares - October 12 at 4:12 PM logoShort Interest Decreases By 15.8% For ADXS - October 11 at 9:27 PM logoHead-To-Head Review: Advaxis (ADXS) vs. Zynerba Pharmaceuticals (ZYNE) - October 5 at 4:30 AM logoEarnings Review and Free Research Report: Advaxis Reported its Q3 FY17 Results - October 3 at 3:18 PM logoInsiders Roundup: Twitter, McKesson Make Biggest Trades - September 30 at 1:43 PM logoAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 1,239,323 Shares - September 26 at 7:24 PM logoAdvaxis, Inc. (ADXS) Rating Reiterated by Cantor Fitzgerald - September 25 at 4:06 PM logoAdvaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference - September 23 at 9:33 AM logo3 Things In Biotech You Should Learn Today: September 20, 2017 - Seeking Alpha - September 20 at 3:26 PM logoTwo Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting - September 19 at 3:33 PM logoCorporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug - September 18 at 3:57 PM logoAdvaxis to Present at Cantor Fitzgerald Global Healthcare Conference - September 18 at 3:57 PM logoCantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Advaxis, Inc. (ADXS) - September 18 at 3:42 AM logoAdvaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright - September 15 at 4:52 PM logoRelative Strength Alert For Advaxis - September 13 at 4:18 PM logoToday's Research Reports on Stocks to Watch: Advaxis and Heat Biologics - September 13 at 4:18 PM logoWhere Do The Chips Fall For Advaxis Going Into Q4 2017? - Seeking Alpha - September 12 at 8:45 PM logoHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today - September 12 at 3:45 PM logo10 Biggest Mid-Day Losers For Thursday - September 12 at 2:28 PM logoHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today - September 12 at 1:57 PM logoAdvaxis, Inc. (ADXS) Announces Quarterly Earnings Results - September 12 at 9:22 AM logoAdvaxis reports 3Q loss - September 11 at 9:10 PM logoAdvaxis Reports Business Update and Third Quarter 2017 Results - Business Wire (press release) - September 11 at 4:07 PM logoAdvaxis Reports Business Update and Third Quarter 2017 Results - September 11 at 4:06 PM logoWhat Does Advaxis Inc’s (ADXS) Share Price Indicate? - September 8 at 8:56 PM logoAdvaxis to Present at Third CRI-CIMT-EATI-AACR International ... - Business Wire (press release) - August 2 at 8:31 PM logoAdvaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival - August 2 at 3:27 PM logoAdvaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders - July 13 at 4:09 PM logoAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim CEO Role - July 8 at 3:16 PM logoCantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis, Inc. (NASDAQ:ADXS) - July 7 at 6:56 PM logoStocks To Watch For July 7, 2017 - Benzinga - July 7 at 5:14 PM logoPre-Open Movers 07/07: (DGLY) (SNCR) (CLB) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - - July 7 at 5:14 PM logoAfter-Hours Movers 07/06: (SNCR) (CLB) (DGSE) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - - July 7 at 2:58 AM logoAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim ... - - July 7 at 2:58 AM logoAdvaxis Announces Change in Leadership - July 6 at 4:52 PM logoAdvaxis CEO Daniel O'Connor resigns - July 6 at 4:52 PM logo3 Things In Biotech You Should Learn Today: June 28, 2017 - June 28 at 3:47 PM logoAdvaxis' Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 - Business Wire (press release) - June 26 at 3:49 PM logoAdvaxis Breaks Down From Key Support Levels (ADXS) - June 17 at 1:48 AM logoAdvaxis At A New 52-Week Low: Panic Or Payload? - Seeking Alpha - June 16 at 3:47 PM logoAdvaxis to Be Featured on Worldwide Business with kathy ireland ® - June 15 at 1:25 AM logoAdvaxis (ADXS) Offers Details on Registrational Trials, EU Regulatory and Commercial Plans - - June 14 at 3:22 PM logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary ... - PR Newswire (press release) - June 5 at 1:36 PM logoSynthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis ... - PR Newswire (press release) - June 1 at 3:28 PM logoAdvaxis teams up with Bristol-Myers on cervical cancer combo - Seeking Alpha - May 31 at 3:20 PM logoCreating Index Tracking Portfolios With Beta Convexity - May 31 at 11:13 AM logoAdvaxis and Bristol-Myers Squibb Announce Clinical Collaboration ... - Business Wire (press release) - May 30 at 3:30 PM logo3 Things In Biotech You Should Learn Today: May 18, 2017 - May 18 at 12:25 PM logoAdvaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac - Business Wire (press release) - May 15 at 3:22 PM logoCommit To Buy Advaxis At $7.50, Earn 16.4% Annualized Using Options - - April 27 at 8:44 PM



Advaxis (ADXS) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.